2026年11月3日星期二
M
Hoàn Vũ Thông Giám
Tin nhanh toàn cầu
Japan can build defense edge on AI, Palantir CEO says— 日经 Nikkei AsiaEU steps up subsea cable buildout to Japan and South Korea— 日经 Nikkei AsiaJapan's Don Quijote drops refund fees for tourists to boost spending— 日经 Nikkei AsiaVietnam solar success prompts rethink of power pricing— 日经 Nikkei AsiaGlobal legal body opens Hong Kong office, boosts city's law hub push— 日经 Nikkei AsiaWill Japanese insurers bring money home? 5 things to know— 日经 Nikkei AsiaChinese steel industry losses snowball as demand falls and costs rise— 日经 Nikkei AsiaSurging costs and China trade war test US farmers' loyalty to Trump— 日经 Nikkei AsiaJapan can build defense edge on AI, Palantir CEO says— 日经 Nikkei AsiaEU steps up subsea cable buildout to Japan and South Korea— 日经 Nikkei AsiaJapan's Don Quijote drops refund fees for tourists to boost spending— 日经 Nikkei AsiaVietnam solar success prompts rethink of power pricing— 日经 Nikkei AsiaGlobal legal body opens Hong Kong office, boosts city's law hub push— 日经 Nikkei AsiaWill Japanese insurers bring money home? 5 things to know— 日经 Nikkei AsiaChinese steel industry losses snowball as demand falls and costs rise— 日经 Nikkei AsiaSurging costs and China trade war test US farmers' loyalty to Trump— 日经 Nikkei Asia

[Correspondence] Communication: the missing pillar of clinical trial governance

Nguồn 柳叶刀 Lancet9 ngày trước
Tóm tắt nội dung

On Sept 2, 2026, negative results of the phase 3 ASPIRE trial (NCT06617429) of apazunersen in Angelman syndrome were announced in a press release issued after…

Trang này chỉ cung cấp tiêu đề và chỉ mục tóm tắt, toàn bộ nội dung và bản quyền đều thuộc về bên phát hành gốc, vui lòng nhấp vào liên kết gốc để đọc.

Đi tới bài gốc
Kênh trực thuộc
Sức khỏe
Khu vực trực thuộc
Vương quốc Anh
Ngôn ngữ gốc
English
Số mục
health-c32be600

Comments 0 comments

No comments yet. Be the first.

[Correspondence] Communication: the missing pillar of clinical trial governance · Hoàn Vũ Thông Giám